Aflibercept 8 mg in real-world neovascular AMD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects real-world data on the effectiveness and safety of intravitreal aflibercept 8 mg in adults with neovascular AMD. Participants receive the drug as part of routine care and are followed over time to assess changes in visual acuity and central retinal thickness, along with any adverse events. Assessments occur at multiple time points up to 12 months to capture short- and long-term outcomes. Data are gathered from treatment-naive and previously treated patients to understand treatment patterns in routine practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged ≥50 years
* A diagnosis of nAMD
* Signed informed patient consent before the start of data collection
* Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice

Exclusion Criteria:

* Participation in an investigational program with interventions outside of clinical routine practice
* Contraindications as listed in the intravitreal aflibercept 8 mg local product information (Ocular or periocular infections, severe active intraocular inflammation, and known allergy to aflibercept or any of its excipients)
* The fellow eye has received intravitreal anti-VEGF treatment other than aflibercept within 28 days prior to enrollment
* Intraocular pressure (IOP) in the study eye \> 25 mmHg
* Additional exclusion criteria for naïve nAMD patients:

  * Any prior ocular treatment in the study eye or systemic treatment for nAMD
* Additional exclusion criteria for pretreated nAMD patients:

  * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
  * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months
  * Dexamethasone implant in the study eye within the last 6 months
  * Any concurrent drug releasing implant in the study eye

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Friendship Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• Beijing Haidian Hospital
  Beijing, Beijing Municipality, China Recruiting
• Nanyang Eye Hospital
  Nanyang, Henan, China Recruiting
• Dalian No.3 People's Hospital
  Dalian, Liaoning, China Recruiting
• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Mingwei Zhao
• Email: dr_zhaomingwei@163.com
• Phone: +86 13801057408

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety test of the Axitinib implant for people with neovascular AMD who finished prior OTX-TKI studies

  This study checks long-term safety of the Axitinib intravitreal implant in people with neovascular AMD who completed prior OTX-TKI studies.

  Recruiting at 8 sites Phase 3 Ocular Therapeutix, Inc. · Bakersfield, California and 7 other locations · NCT07516132

• Ixo-vec gene therapy versus aflibercept for wet age-related macular degeneration (AQUARIUS)

  This study tests whether a single injection of Ixo-vec gene therapy can maintain or improve vision as well as regular aflibercept injections in adults aged 50 and older with active neovascular (wet) AMD.

  Recruiting at 79 sites Phase 3 Adverum Biotechnologies, Inc. · Mesa, Arizona and 78 other locations · NCT07482176

• LX102 gene therapy for neovascular (wet) age-related macular degeneration

  This trial will test whether a single subretinal injection of LX102 gene therapy can maintain or improve vision in people aged 50–80 with active neovascular (wet) AMD who previously responded to aflibercept.

  Recruiting at 36 sites Phase 3 Innostellar Biotherapeutics Co.,Ltd · Hefei, Anhui and 35 other locations · NCT07317934

• Single intravitreal injection of 4D-150 for macular neovascularization from age-related macular degeneration

  This trial will try a single eye injection of 4D-150 versus standard aflibercept in adults 50 and older with neovascular (wet) AMD to see if it controls disease activity.

  Recruiting at 11 sites Phase 3 4D Molecular Therapeutics · Scottsdale, Arizona and 125 other locations · NCT07064759

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.